Skip to main content
Toggle navigation
Search
Home
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Red Recording
Sig Meeting
Like
Tweet
Print
Stephane A. Regnier, PhD
Lundbeck LLC
Poster(s):
(T 15) Real-World Impact of Eptinezumab Treatment on Migraine-Related Cognitive Symptoms in Participants in Whom ≥1 Prior CGRP-Targeted Therapy had Failed: 12-Month Results of a Prospective Study
(T 17) Dose escalation to eptinezumab 300 mg: A subgroup analysis of the 60-week, open-label SUNSET trial in Japanese participants with chronic migraine who experienced suboptimal response